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Menne et al., 2015Toll-like receptor (TLR) signaling has been implicated to play a signiﬁ-
cant role in the context of cytokine-induced ‘curing’ of HBV-infected
cells. In previous studies, the oral small molecule TLR7 agonist GS-
9620 caused a marked HBsAg reduction in chronically HBV-infected
chimpanzees. The present study by Menne et al. evaluated GS-
9620 in the HBV Woodchuck animal model demonstrating that short
duration treatment with the TLR7 agonist was able to induce a sus-
tained antiviral response which is likely due to the induction of local
interferon-alpha and natural killer cell and CD8+ T cell responses
as well as activation of B cells. A striking reduction in the incidence
of hepatocellular carcinoma was also observed in the treated animals.
The safety and efﬁcacy of GS-9620 (attaining a functional cure?) will
be further developed in a phase II multi-center study in virally-
suppressed subjects with chronic hepatitis B (ClinicalTrials.gov
NCT02166047).LIVER CANCER
ECT2 promotes HCC
recurrence
ECT2 is encoded by epithelial
cell transforming 2 (ECT2, alias
ARHGEF31). It is a guanine
nucleotide exchange factor that
catalyzes the exchange of GDP
for GTP on the Rho family
members of small GTPases, like
RHOA, RHOC, RAC1, and
CDC42. Rho GTPases via actin
activation coordinate cell migra-
tion and affect cancer invasion
and metastasis, among other
processes. Because ECT2 is a
major regulator of Rho GTPases,
Chen et al. asked whether this
protein plays a role in HCC
recurrence after surgical resec-
tion. Performing expression
microarray conﬁrmed an
overexpression of ECT2 tran-
scripts in HCC tissues compared
with non-tumoral liver. Moreover
they found that ECT2Open access under CC BY-NC-ND license.overexpression is associated
with early recurrent HCC disease
and poor survival. Elegant
in vitromechanistic studies led to
a scenario in which ECT2 via the
activation of Rho GTPases
stimulates MAP kinases ERK to
promote early HCC recurrence.
These ﬁndings suggest that
ECT2 could be a target for
novel therapies aimed to pre-
vent HCC recurrence.
LIVER INJURY
Shbp3 and hepatocyte
lipotoxicity, iNKT cells
promote alcohol-
induced liver
inﬂammation, role of
epiplakin in liver injury,
nanoparticle-based
therapy for autoimmune
liver disease
Sustained activation (i.e., phos-
phorylation) of c-Jun N-terminalJournal of Hepatology 201kinase (JNK, a MAP kinase) by
saturated fatty acids plays a role
in lipotoxicity and the develop-
ment of NASH. Win et al.
investigating in vitro phospha-
tidic acid (PA)-induced hep-
atocyte toxicity now show that
JNK activation is dependent on
upstream stimulation of PRKR-
like endoplasmic reticulum (ER)
kinase (PERK) indicating the
engagement of an unfolded pro-
tein response due to PA-induced
ER stress. They also found that
the interplay of activated JNK
with the mitochondrial protein
Sh3bp-5 (also known Sab) leads
to impaired mitochondrial res-
piration (i.e., stress of the orga-
nelle), ROS production,
sustained JNK activation, and
apoptosis. These ﬁndings sug-
gest that ER stress may med-
iate hepatocyte lipotoxicity at
least in part via inducing
Sh3bp-5–elicited mitochon-
drial stress.5 vol. 62 j 1221–1224Intracellular pattern recogni-
tion receptors that assemble into
high-molecular weight, caspase-
1-activating platforms called
‘inﬂammasomes’ (e.g., NLRP3)
control maturation and secretion
of interleukins (IL) such as IL-1b
and IL-18, which both are potent
pro-inﬂammatory cytokines. In
mouse models of alcohol-in-
duced steatohepatitis the NLRP3
inﬂammasome is activated in
Kupffer cells, resulting in the
release of IL-1b. However, little
is known about the contribution
of IL-1b to liver inﬂammation. Cui
et al. addressed this question
using a chronic plus single-binge
ethanol consumption model in
wild-type and Ja18/ mice that
are deﬁcient in invariant natural
killer T (iNKT) cells. They show
that Kupffer cell-derived IL-1b,
produced after alcohol-
induced NLRP3 activation,
recruits and activates hepatic
iNKT cells, subsequently
Szabo et al., 2015
JOURNAL OF HEPATOLOGYpromoting liver inﬂammation
and neutrophil inﬁltration, and
inducing alcoholic liver injury.
Therefore, IL-1b could be a tar-
get for anti-inﬂammatory thera-
pies in patients with alcoholic
liver disease.
Epiplakin (encoded by
Eppk1) is a member of the plakin
protein family which maintains
the integrity of keratin inter-
mediate ﬁlament networks in
epithelial cells. Epiplakin-deﬁ-
cient (Eppk1/) mice have no
obvious spontaneous phenotype
but the consequences of Eppk1
deﬁciency in the context of liver
injury is unknown. For this rea-
son, Szabo et al. investigatedPhysi
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1222wild-type and Eppk1/ mice
subjected to common bile duct
ligation (CBDL) or fed with a 3,5-
diethoxycarbonyl-1,4-dihydrocol-
lidine (DDC)-containing diet.
After CBDL and DDC treatment,
Eppk1/ mice exhibited more
marked liver injury and their liv-
ers contained larger amounts of
hepatocellular keratin granules,
indicating impaired disease-
induced keratin network
reorganization. Overall their data
are consistent with the view that
epiplakin plays a protective
role during experimental liver
injuries by chaperoning dis-
ease-induced keratin
reorganization.AlbCrePt
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Development of NASH
Journal of Hepatology 201Liver sinusoidal endothelial
cells (LSECs) can contribute to
hepatic tolerance through their
ability to induce CD4+ Foxp3+
regulatory T cells (Tregs).
Carambia et al. asked whether
the Treg-inducing potential of
LSECs could be used for the
treatment of autoimmune dis-
ease. To address this question
they engineered a polymeric
nanoparticle (NP) carrier that
selectively delivers autoantigen
peptides to LSECs in vivo. Next
they investigated whether
administration of LSEC-targeting
autoantigen peptide-loaded NPs
protects mice with experimental
autoimmune encephalomyelitis.
They found that selective
delivery of autoantigen pep-
tides to LSECs by NPs
induces antigen-speciﬁc
Tregs and is associated with
improvement of autoimmune
disease. These ﬁndings
emphasize the importance of
Treg-induction by LSECs in
obtaining immune tolerance.
NON-ALCOHOLIC
FATTY LIVER DISEASE
(NAFLD)
Hyperuricemia, celiac
disease, therapies with
farnesoid X receptor
(FXR) antagonists or
cannabinoidsenflox/flox
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5 vol. 62 j 1221–1224NAFLD is frequently associated
with other medical conditions. In
this issue, two large studies liked
NAFLD with hyperuricemia and
celiac disease. Hyperuricemia
is a common feature of patients
with obesity. Xu et al. carried out
a human and experimental study
that showed that NAFLD signiﬁ-
cantly increases the risk of inci-
dent hyperuricemia, and that
xanthine oxidase is a mediator of
the relationship between two
conditions. Interestingly, they
provide evidence that targeting
xanthine oxidase could have
beneﬁcial effects on NAFLD.
Celiac disease alters intestinal
permeability and gluten-free diet
often causes weight gain. Reilly
et al. performed a population-
based cohort study, demonstrat-
ing that patients with celiac dis-
ease are at increased risk of
NAFLD compared to the general
population. This epidemiological
study suggests that upon diag-
nosis, patients with celiac dis-
ease should be advised to avoid
weight gain and subsequent
NAFLD development.
Besides changes in lifestyle,
current efforts have been made
to identify new therapeutic tar-
gets for patients with NAFLD.
There is recent evidence that
bile acids contribute to NAFLD
and are targets for therapy. In
this issue, Mueller et al. demon-AMPK
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From the Editor’s deskstrate that by exerting FXR-an-
tagonistic effects, treatment with
ursodeoxycholic acid strongly
impacts on cholesterol and bile
synthesis and induces neutral
lipid accumulation in both liver
and visceral fat. These interest-
ing results provide evidence that
bile acids regulate steatosis and
open new pathways for thera-
peutic interventions. Endoge-
nous cannabinoids are one of
the most promising therapeutic
targets for NAFLD. In this issue,
Silvestri et al. provide evidence
that delta9-tetrahydrocannabi-
varin and cannabidiol, two
endogenous cannabinoids,
improve insulin sensitivity and
reduce experimental liver
steatosis. These results conﬁrm
that this family of substances
has enormous potential to treat
patients with metabolic syn-
drome and NAFLD.ALCOHOLIC LIVER
DISEASE (ALD)
Activating alcohol
metabolism
The development of targeted
therapies for ALD requires the
identiﬁcation of the molecular
drivers. It is not well known
whether alcohol-metabolizing
enzymes contribute to liver
damage. High-throughputscreening has previously identi-
ﬁed N-(1,3-benzodioxol-5-yl-
methyl)-2,6-dichlorobenzamide
(Alda-1) as a potent activator of
aldehyde dehydrogenase,
mitochondrial (also known as
ALDH class 2). In this issue of
the Journal, Zhong et al.
demonstrates that Alda-1, a
speciﬁc activator of ALDH2,
accelerates acetaldehyde clear-
ance and attenuates liver dam-
age after alcohol exposure. This
intriguing study suggests that
ALDH class 2 is a promising
molecular target and Alda-1
has therapeutic potential for
treating ALD.PEDIATRIC LIVER
DISEASE
Intestinal failure-
associated liver disease
Intestinal failure due to the loss
of ileum is associated with
chronic liver injury, yet the
underlying mechanisms are
unknown. In this issue, Mutanen
et al. investigated role of ﬁbro-
blast growth factor 19 (FGF-19)
and pro-inﬂammatory cytokines.
In pediatric onset intestinal fail-
ure, loss of ileum decreases
serum FGF-19 concentration
paralleling hepatic inﬂammation
and ﬁbrosis along with increased
cholesterol synthesis. ThisJournal of Hepatology 201study suggests that FGF-19
may contribute to the patho-
genesis of liver disease asso-
ciated to this syndrome.HEPATITIS C
STARTVerso 1 – A
phase III trial evaluating
second-wave protease
inhibitor faldaprevir
triple therapy
Although interferon-based regi-
men will ultimately disappear in
the management of chronic HCV
infection (due to the rapid devel-
opment of interferon-free DAA
regimens), and faldaprevir may
ultimately have a limited clinical
role as Boehringer Ingelheim
stopped their HCV development
program, the results of the cur-
rent phase III faldaprevir triple
therapy study by Ferenci et al.
marks an important milestone in
HCV therapeutics. Relevant
questions have been addressed
within this study especially
regarding the importance of
dosage and duration of protease
inhibitor applications in general,
predictors of treatment outcome
including the relevance of base-
line resistance associated vari-
ants and viral polymorphisms but
also the safety of second-wave
protease inhibitor regimens.5 vol. 62 j 1221–1224HEPATITIS B
Deﬁning mortality risk
in HBV carriers, risk
factor-associated
hepatitis virus
screening
A population-based study from
two Eastern French administra-
tive areas with a total population
of about one million indicates an
increased overall mortality from
chronic HBV infection of 70% as
compared to the general pop-
ulation. After a median follow-up
of over 8 years, signiﬁcant
increased risk of death was due
to hepatocellular carcinoma,
non-Hodgkin’s lymphoma
(NHL) and chronic liver disease.
Thus, the study by Montuclard
et al. conﬁrms previous ﬁndings
which have linked chronic HBV
to the development of NHL.
Unfortunately, the effect of
antiviral treatment could not be
investigated in the current
study.
The study by Wolffram et al.
represents one of the largest
prospective studies which
evaluates the prevalence of
chronic HBV and HCV infec-
tion in the primary care setting
(named ‘Check-up 35+’) in
Germany in a cohort of 21,000
persons, and is probably the
ﬁrst which critically evaluates the
clinical beneﬁt of a hepatitis1223
Endothelial cells
Normal hepatocytes
Kupffer cell
iNKT cells
TNF-αIL-1β
↑ E-selectin
Neutrophils
Steatotic hepatocytes Hepatocellular necrosis
Migration
NLRP3
ASC
Pro-casp1
Activated Casp1
Pro-IL-1β
IL-1R
E-selectin ligand
LPS?
Alcohol
NLRP3
inflammasome
activation
Cui et al., 2015
JOURNAL OF HEPATOLOGYscreening according to risk
scenarios deﬁned by national
treatment guidelines. Three easy
to apply questions could be
extracted for daily clinical routine
which were signiﬁcantly asso-
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